Shingles Vaccine Cuts Dementia Risk by 20%

Scientists have discovered something remarkable hiding in plain sight: the shingles vaccine appears to prevent dementia, with some studies showing a 20 percent reduction in risk.

For years, researchers noticed older adults who got vaccinated against shingles seemed less likely to develop dementia. The pattern kept showing up, but scientists worried the data might be misleading—maybe healthier people simply chose to get vaccinated more often.

Then researchers found a clever way to test the connection. They studied vaccine rollouts in Australia, Canada, and Wales, where sudden age cutoffs created natural comparison groups. In Wales, people aged 71 to 78 became eligible for the vaccine on September 1, 2013, while those turning 80 were permanently ineligible.

The results were striking. Over seven years, the vaccinated group showed 20 percent fewer dementia diagnoses compared to the ineligible group. An Australian study found similar results: only 3.7 percent of eligible people developed dementia versus 5.5 percent of ineligible people over 7.4 years.

The protection appears to be entirely unintentional. Shingles vaccines target the varicella-zoster virus that causes chickenpox in childhood and can reactivate decades later as painful shingles. The vaccine simply helps the immune system keep that dormant virus in check.

The newer vaccine, Shingrix, may offer even better protection. Released in 2017, it's 90 to 97 percent effective at preventing shingles compared to the older vaccine's 51 percent. Early data suggests it might provide stronger dementia protection too, meaning previous studies may have underestimated the benefit.

Recent research hints the vaccine may also slow biological aging and reduce inflammation markers. Eileen Crimmins from the University of Southern California notes the vaccine may play a role in healthy aging beyond just preventing illness.

Why This Inspires

If a new drug cut dementia risk by 20 percent, it would be hailed as a medical breakthrough. This vaccine has been quietly doing exactly that for years, sitting on pharmacy shelves waiting to help. The science keeps getting stronger with each new study across different countries and populations.

The protection appears real, repeatable, and accessible right now for anyone over 50.